May 02, 2025

Use of CAD/CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer

The use of computer-aided design and manufacturing (CAD/CAM) techniques for planning jaw reconstructions for patients with head and neck cancer can potentially improve the duration of the surgery and ...

The ASCO Post

May 01, 2025

Case Report of Multiple Mucoceles Due to Persistent Lip Biting Related to Post-Traumatic Stress Disorder

It is not unusual for PTSD patients to exhibit body-focused repetitive behavior that may involve persistent lip biting and other detrimental repeated behaviors.

Compendium

May 01, 2025

Who Is at Risk for LSCD?

Discover the vital role of limbal stem cells in maintaining ocular surface health and the challenges associated with limbal stem cell deficiency.

Contact Lens Spectrum

May 01, 2025

#EBNewProducts: Retail Fashion

Trending style for the optical + beyond

Eyecare Business

May 01, 2025

The Beauty Perspective

Eye for Beauty: Two ODs who have successfully integrated aesthetic enhancements into their optometric practices share how to set your office up for success.

Eyecare Business

May 01, 2025

Early-Onset Atopic Dermatitis Increases Risk of Pediatric Uveitis

Chronic uveitis can “lead to ocular damage, potentially resulting in cataracts, glaucoma, and amblyopia,” researchers noted.

Conexiant

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 29, 2025

First Cell-Based Gene Therapy Approved

FDA approves Zevaskyn (pz-cel), a cell-based gene therapy, for the treatment of recessive dystrophic epidermolysis bullosa.

Reuters